CytoDyn's Leronlimab Shows PD-L1 Induction, Long-Term Survival in mTNBC
Event summary
- CytoDyn presented new data on leronlimab at AACR 2026, showing PD-L1 induction and long-term survival in mTNBC patients.
- Retrospective analysis of 28 mTNBC patients found 17.9% alive after 60+ months with leronlimab treatment.
- Leronlimab-mediated CCR5 inhibition modulated immune checkpoint signaling, enhancing PD-L1 expression.
- Higher leronlimab doses and combination with ICIs correlated with improved survival outcomes.
The big picture
CytoDyn's findings at AACR 2026 highlight the potential of CCR5 inhibition to overcome immunotherapy resistance in mTNBC, a field with limited treatment options. The data suggest leronlimab could prime tumors for ICIs, addressing a critical unmet need in aggressive breast cancer subtypes. The long-term survival signals, if replicated, could position CytoDyn as a key player in precision oncology.
What we're watching
- Clinical Validation
- Whether leronlimab's PD-L1 induction can translate into broader mTNBC treatment approvals.
- Combination Strategies
- The pace at which CytoDyn advances leronlimab-ICI combination therapies into late-stage trials.
- Market Differentiation
- How CytoDyn positions leronlimab against existing CCR5 inhibitors in oncology.
Related topics